NO20082823L - Spirosykliske forbindelser som HDAC-innhibitorer - Google Patents

Spirosykliske forbindelser som HDAC-innhibitorer

Info

Publication number
NO20082823L
NO20082823L NO20082823A NO20082823A NO20082823L NO 20082823 L NO20082823 L NO 20082823L NO 20082823 A NO20082823 A NO 20082823A NO 20082823 A NO20082823 A NO 20082823A NO 20082823 L NO20082823 L NO 20082823L
Authority
NO
Norway
Prior art keywords
compounds
diseases
present
proliferation
prevention
Prior art date
Application number
NO20082823A
Other languages
English (en)
Inventor
Scott C Berk
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082823L publication Critical patent/NO20082823L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse gjelder en ny klasse av substituerte spirosykliske forbindelser representert ved Formel (II). Disse forbindelsene kan inhibere histondeacetylase og er egnede for anvendelse for selektiv induksjon av terminal differensiering og arrest av cellevekst og/eller apoptose av neoplastiske celler, slik at proliferasjonen av slike celler inhiberes. Følgelig er forbindelsene ifølge foreliggende oppfinnelse anvendbare for behandling av en pasient med en tumor som særpreges ved proliferasjon av neoplastiske celler. Forbindelsene ifølge oppfinnelsen kan også være anvendbare for forebyggelse og behandling av TRX-formidlede sykdommer, for eksempel autoimmune sykdommer, allergiske sykdommer og betennelsessykdommer, og for forebyggelse og/eller behandling av sykdommer i sentralnervesystemet (CNS), for eksempel neurodegenerative sykdommer. Foreliggende oppfinnelse tilveiebringer videre farmasøytiske preparater som omfatter forbindelsene ifølge foreliggende oppfinnelse, og sikre doseringsskjemaer for disse farmasøytiske preparatene, som er lette å følge og som fører til en terapeutisk effektiv mengde av disse forbindelsene in vivo.
NO20082823A 2005-11-23 2008-06-20 Spirosykliske forbindelser som HDAC-innhibitorer NO20082823L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73932405P 2005-11-23 2005-11-23
PCT/US2006/044948 WO2007061978A1 (en) 2005-11-23 2006-11-17 Spirocyclic compounds as hdac inhibitors

Publications (1)

Publication Number Publication Date
NO20082823L true NO20082823L (no) 2008-08-19

Family

ID=37811669

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082823A NO20082823L (no) 2005-11-23 2008-06-20 Spirosykliske forbindelser som HDAC-innhibitorer

Country Status (17)

Country Link
US (4) US7544695B2 (no)
EP (1) EP1954698B1 (no)
JP (1) JP4921485B2 (no)
KR (1) KR20080069630A (no)
CN (1) CN101312976A (no)
AR (1) AR057579A1 (no)
AT (1) ATE434618T1 (no)
AU (1) AU2006318773B2 (no)
BR (1) BRPI0618904A2 (no)
CA (1) CA2629777C (no)
DE (1) DE602006007482D1 (no)
DO (1) DOP2006000260A (no)
NO (1) NO20082823L (no)
PE (1) PE20071084A1 (no)
RU (1) RU2008125068A (no)
TW (1) TW200804381A (no)
WO (2) WO2007061880A1 (no)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2006240246A1 (en) 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
AU2006240248A1 (en) 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
JP2008546793A (ja) 2005-06-24 2008-12-25 メルク エンド カムパニー インコーポレーテッド 修飾マロン酸誘導体
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
KR101495611B1 (ko) * 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
CA2651681A1 (en) * 2006-05-18 2007-11-29 Merck & Co., Inc. Aryl-fused spirocyclic compounds
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
FR2920774B1 (fr) * 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009037542A2 (en) * 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
US20100317679A1 (en) * 2007-09-21 2010-12-16 Ligand Pharmaceuticals, Inc. Substituted aryl-fused spirocyclic amines
US8653068B2 (en) * 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2311840A1 (en) 2009-10-13 2011-04-20 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
EP2110377A1 (en) * 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2010025375A1 (en) 2008-08-29 2010-03-04 Treventis Corporation Compositions and methods of treating amyloid disease
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8580808B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
WO2010051497A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
CN101397295B (zh) * 2008-11-12 2012-04-25 深圳微芯生物科技有限责任公司 作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010143803A2 (en) * 2009-06-08 2010-12-16 Industry Foundation Of Chonnam National University New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same
US8580809B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
MX355907B (es) 2011-02-02 2018-05-04 Vertex Pharma Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos.
JP5940562B2 (ja) 2011-02-18 2016-06-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
MX347982B (es) 2011-03-14 2017-05-22 Vertex Pharma Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos.
KR20140011383A (ko) 2011-03-16 2014-01-28 크리에이티브 테라퓨틱스 게엠베하 치환된 디페닐 유도체
CN103492371B (zh) * 2011-03-18 2015-11-25 山东亨利医药科技有限责任公司 含有螺环的二氢吡唑类化合物
EP2557075A1 (de) 2011-08-09 2013-02-13 Trin Therapeutics GmbH Neue Triazenverbindungen zur Behandlung von Krebs
RU2014116229A (ru) 2011-09-23 2015-10-27 Даблхил Гмбх Новые соединения изоцианата и изотиоцианата для лечения злокачественных новообразований
ES2716049T3 (es) 2012-07-13 2019-06-07 Pain Therapeutics Inc Un método para inhibir la fosforilación de tau
JP6566867B2 (ja) 2012-07-13 2019-08-28 ペイン セラピューティクス インコーポレイテッド 生きている患者でのアルツハイマー病アッセイ
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
WO2014143666A1 (en) 2013-03-15 2014-09-18 Biomarin Pharmaceutical Inc. Hdac inhibitors
CA2903813C (en) 2013-03-15 2023-08-29 Epizyme, Inc. Carm1 inhibitors and uses thereof
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
JP6643545B2 (ja) * 2014-03-14 2020-02-12 ラクオリア創薬株式会社 Ｔｒｐｍ８拮抗剤としてのアザスピロ誘導体
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
BR112017000762A2 (pt) 2014-07-15 2017-11-21 Gruenenthal Gmbh derivados de azaspiro(4.5)decano substituído.
JP2017527594A (ja) * 2014-09-17 2017-09-21 エピザイム，インコーポレイティド コアクチベーター関連アルギニンメチルトランスフェラーゼ１（ｃａｒｍ１）阻害剤の塩、共結晶、非晶質形態、および結晶形態
AU2015360270B9 (en) 2014-12-12 2019-12-05 Regenacy Pharmaceuticals, Llc Piperidine derivatives as HDAC1/2 inhibitors
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
HUE049481T2 (hu) * 2015-04-03 2020-09-28 Recurium Ip Holdings Llc Spirociklusos vegyületek
RU2720678C2 (ru) * 2015-07-02 2020-05-12 Байомарин Фармасьютикал Инк. Ингибиторы гистондеацетилазы
EP3317279B1 (en) * 2015-07-03 2021-01-27 H. Hoffnabb-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors
LT3319959T (lt) * 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN105601617B (zh) * 2016-03-24 2019-02-22 山东省科学院生物研究所 一种邻二氮杂环化合物及其制备方法与应用
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
CN106397575A (zh) * 2016-10-20 2017-02-15 上海懿贝瑞生物医药科技有限公司 一种具有胞外组蛋白毒性抑制作用的多肽制备方法及用途
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
TW201829381A (zh) * 2016-12-22 2018-08-16 美商拜奧馬林製藥公司 組蛋白脫乙醯基酶抑制劑
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CN119751456A (zh) * 2018-04-16 2025-04-04 C4医药公司 螺环化合物
KR102833434B1 (ko) 2018-09-27 2025-07-15 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. 인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체
EP3876928B1 (en) * 2018-11-08 2024-10-23 Merck Sharp & Dohme LLC Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
CN117177744A (zh) 2021-01-29 2023-12-05 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
MX2023015436A (es) 2021-06-26 2024-02-21 Cedilla Therapeutics Inc Inhibidores de cdk2 y metodos de uso de los mismos.
EP4422621A4 (en) * 2021-10-27 2025-08-27 Merck Sharp & Dohme Llc SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF
WO2023125476A1 (zh) * 2021-12-30 2023-07-06 成都先导药物开发股份有限公司 螺环化合物及其双功能化合物和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
NZ319673A (en) * 1995-10-17 2000-06-23 Astra Pharma Prod Quinazoline compounds for inflammatory disorders such rheumatoid arthritis or osteoarthritis
US5833102A (en) * 1996-11-13 1998-11-10 Jacobson; Jeffery Thomas Portable vehicle-mounted support
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
ATE250604T1 (de) 1999-10-27 2003-10-15 Millennium Pharm Inc Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
JP3558079B2 (ja) 2001-03-19 2004-08-25 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
US6784173B2 (en) * 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
MXPA04008796A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1541574A4 (en) 2002-09-18 2007-06-20 Ono Pharmaceutical Co TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT
AU2003292888A1 (en) 2002-12-27 2004-07-22 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
IN2003CH00929A (no) * 2003-11-13 2008-10-06
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)

Also Published As

Publication number Publication date
US20110098268A1 (en) 2011-04-28
US20130131041A1 (en) 2013-05-23
TW200804381A (en) 2008-01-16
CN101312976A (zh) 2008-11-26
AR057579A1 (es) 2007-12-05
US8686020B2 (en) 2014-04-01
WO2007061978A1 (en) 2007-05-31
US7544695B2 (en) 2009-06-09
DOP2006000260A (es) 2007-06-30
US20070117824A1 (en) 2007-05-24
RU2008125068A (ru) 2009-12-27
PE20071084A1 (es) 2008-01-10
AU2006318773A1 (en) 2007-05-31
DE602006007482D1 (de) 2009-08-06
JP2009516743A (ja) 2009-04-23
EP1954698A1 (en) 2008-08-13
US8349825B2 (en) 2013-01-08
EP1954698B1 (en) 2009-06-24
AU2006318773B2 (en) 2012-03-22
CA2629777A1 (en) 2007-05-31
WO2007061880A1 (en) 2007-05-31
JP4921485B2 (ja) 2012-04-25
BRPI0618904A2 (pt) 2016-09-13
CA2629777C (en) 2011-08-16
ATE434618T1 (de) 2009-07-15
KR20080069630A (ko) 2008-07-28
US7834026B2 (en) 2010-11-16
US20090209566A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
NO20082823L (no) Spirosykliske forbindelser som HDAC-innhibitorer
WO2007087129A3 (en) Fluorinated arylamide derivatives
WO2007087130A3 (en) Hydroxyalkylarylamide derivatives
WO2007127137A3 (en) Disubstituted aniline compounds
WO2007100657A3 (en) Inhibitors of histone deacetylase
WO2008010985A3 (en) Phosphorus derivatives as histone deacetylase inhibitors
WO2009005638A3 (en) Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
WO2007136605A3 (en) Aryl-fused spirocyclic compounds
WO2007055942A3 (en) Substituted nicotinamide compounds
WO2005053610A3 (en) Diamine and iminodiacetic acid hydroxamic acid derivatives
WO2005034880A3 (en) Thiophene and benzothiophene hydroxamic acid derivatives
WO2007002248A3 (en) Modified malonate derivatives
WO2007055941A3 (en) Histone deacetylase inhibitors with aryl-pyrazolyl motifs
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
DE60331219D1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
WO2004089293A3 (en) Hydroxamic acid compounds and methods of use thereof
WO2014100071A3 (en) Substituted pyrrolopyrimidines as hdm2 inhibitors
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
ATE374200T1 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
MX2011012752A (es) Derivados de naftalenocarboxamida como inhibidores de proteina quinasa y de histona desacetilasa, procedimientos de preparacion y usos de los mismos.
PL1656348T3 (pl) Pochodne acetylenu jako inhibitory deacetylazy histonowej
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
EA201500769A1 (ru) Ингибиторы е1 активирующих ферментов
DK1692097T3 (da) Tricykliske hydroxamat- og benzamidderivater, sammensætninger og fremgangsmåder

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application